Activation of the PTEN/mTOR/STAT3 pathway in breast cancer stem-like cells is required for viability and maintenance

By Jiangbing Zhou, J. Wulfkuhle, Hao Zhang, Peihua Gu, Yanqin Yang, Jianghong Deng, J. Margolick, L. Liotta, E. Petricoin, Ying Zhang. Proceedings of the National Academy of Sciences of the United States of America, 2007

688 citations recorded by the source corpus.

Subfields: Cancer Research, Molecular Biology, Oncology

View Paper: https://www.semanticscholar.org/paper/478f06a427f2135179fc78bac39c4fa20f5c3759

How researchers see this paper

The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.

In Cancer Research

In Molecular Biology

In Oncology

Citations in the corpus

Targeting tumor-infiltrating macrophages decreases tumor-initiating cells, relieves immunosuppression and improves chemotherapeutic responses (2012, background): “Inflammation and TICs STAT3 activity has been shown to be required for the expansion and maintenance of cancer stem cells in several cancers (33, 34).”
PTEN/PI3K/Akt pathway regulates the side population phenotype and ABCG2 activity in glioma tumor stem-like cells (2009, background): “Loss of PTEN Increases the SP Fraction and Highly Favors the MDR Phenotype Akt has been shown to regulate the SP phenotype in bone marrow cells, and similar effects were reported in breast cancer cells after PTEN loss (Zhou et al., 2007).”
Multifaceted role of mTOR (mammalian target of rapamycin) signaling pathway in human health and disease (2023, background): “131 Treatment of HCC with branched-chain amino acids resulted in the activation of mTORC1.”
Targeting cancer stem cell pathways for cancer therapy (2020, background): “328 Inhibition of TORC1/2 increases FGF1 and Notch1 expression.”
The mTOR kinase differentially regulates effector and regulatory T cell lineage commitment. (2009, result): “However, our findings are consistent with recent observations in tumor cells and in IL-6-induced insulin resistance implicating a role for mTOR in STAT3 activation (Kim et al., 2008; Zhou et al., 2007).”
Regulation of mTORC1 and its impact on gene expression at a glance (2013, background): “Consistent with this study, activation of the mTORC1– STAT3 pathway is required for the viability and the maintenance of breast cancer stem-like cells (Zhou et al., 2007).”
EMT, cancer stem cells and drug resistance: an emerging axis of evil in the war on cancer (2010, background): “For example, the mTOR and stat3 pathways cooperate to promote the proliferation of breast CSCs (Zhou et al., 2007).”
Roles of the Raf/MEK/ERK and PI3K/PTEN/Akt/mTOR pathways in controlling growth and sensitivity to therapy-implications for cancer and aging (2011, background): “Targeting the Ras/Raf/MEK/ERK and Ras/PI3K/PTEN/mTOR pathways could be very important in terms of CIC elimination.”
Tumour-initiating cells: challenges and opportunities for anticancer drug discovery (2009, background): “In addition, activation of the PTEN–mammalian target of rapamycin ( mTOR )–signal transducer and transcription activator 3 ( STAT3 ) pathway in breast tumour-initiating cells is required for their viability and maintenanc”